Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489809 | 0.88 | TDP1 (0.46) | TP53ALOX15ESR1TSHRALDH1A1 | |
| SCHEMBL704307 | 0.86 | NPC1 (0.49) | TP53ALOX15ESR1NPC1JAK2 | |
| SCHEMBL3458582 | 0.84 | NPC1 (0.51) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL707050 | 0.84 | NPC1 (0.51) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL1685969 | 0.84 | NPC1 (0.51) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL16415141 | 0.84 | NPC1 (0.51) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL7651322 | 0.84 | NPC1 (0.51) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL16415177 | 0.84 | NPC1 (0.51) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL16414653 | 0.84 | NPC1 (0.51) | TP53NPC1JAK2RAB9APAX8 | |
| Chloromethane SCHEMBL7281088 | 0.84 | NPC1 (0.44) | TP53ALOX15ESR1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2478981-B1 | SILVER-(CONJUGATED COMPOUND) COMPLEX | SUMITOMO CHEMICAL CO (JP) | 2020-12-23 | — | — | EP | disclosed |
| EP-3390372-B1 | BENZAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES | BASF SE (DE) | 2020-06-03 | — | — | EP | disclosed |
| CN-104804048-B | N substituted benzyl amino phosphine clamp ring ruthenium diphosphine compounds and its preparation method and application | 洛阳师范学院 | 2017-09-22 | — | — | CN | disclosed |
| US-9704612-B2 | Composition of silver-conjugated compound composite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-07-11 | — | — | US | disclosed |
| EP-2841433-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL CO (JP) | 2017-06-21 | — | — | EP | disclosed |
| US-9412487-B2 | Silver-(conjugated compound) composite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9380782-B2 | Tetrazolinone compounds and its use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-07-05 | — | — | US | disclosed |
| EP-2841433-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | Sumitomo Chemical Company Limited (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20150031733-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20140001422-A1 | COMPOSITION OF SILVER-CONJUGATED COMPOUND COMPOSITE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-02 | — | — | US | disclosed |
| WO-1998037150-A1 | TRIFLUOROMETHYL-SUBSTITUTED AZO DYES | BASF AKTIENGESELLSCHAFT (DE) | 1998-08-27 | — | — | WO | disclosed |
| EP-0837864-A1 | NOVEL QUINOXALINE- AND QUINOXALINYLALKANE-PHOSPHONIC ACIDS | Novartis AG (CH) | 1998-04-29 | — | — | EP | disclosed |
| US-5688823-A | ANTILIPEMIC AGENTS, ANTIGLYCEMIC AGENTS, OBESITY, GLUCOSE TOLERANCE INSUFFICIENCY, INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1997-11-18 | — | — | US | disclosed |
| WO-1997003079-A1 | NOVEL QUINOXALINE- AND QUINOXALINYLALKANE-PHOSPHONIC ACIDS | NOVARTIS AG (CH) | 1997-01-30 | — | — | WO | disclosed |
| US-5578620-A | TREATMENT OF DIABETES AND HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1996-11-26 | — | — | US | disclosed |
| EP-0705834-A1 | Quinoxaline-2,3-diones with an azaheterocyclic fused ring | CIBA-GEIGY AG (CH) | 1996-04-10 | — | — | EP | disclosed |
| EP-0705835-A1 | Quinoxalic-2,3-diones with an oxa or thiaheterocyclic fused ring | CIBA-GEIGY AG (CH) | 1996-04-10 | — | — | EP | disclosed |
| EP-0678511-A2 | Thiazolidine and oxazolidine derivatives, their preparation and their medical use | SANKYO COMPANY LIMITED (JP) | 1995-10-25 | — | — | EP | disclosed |
| EP-0172789-A2 | Process for the sulfation of compounds containing a hydroxyethyl group | CIBA-GEIGY AG (CH) | 1986-02-26 | — | — | EP | disclosed |
| US-4157333-A | CONDENSATION OF 1,2-METHYLENEDIOXYBENZENE WITH N-ALKYLOORMANILIDE, HYDROLYSIS | MITSUI TOATSU CHEMICALS, INC. (JP) | 1979-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031733-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | CBR3, CYP51A1, CYP8B1 | TP53 4413/4885ALOX15 1685/4885ESR1 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.